To bring more perspective to the above statement, there are classical pieces of evidence of food habits playing an essential role in disease incidence
As of 2026, Retatrutide is progressing through Phase 3 clinical trials, with high anticipation for its potential approval as a therapeutic agent
Ramesh M, Janani R, Deepa C, Rajeshkumar L
Its worth noting that this difficulty in absorbing Vitamin B12 is different from Vitamin B12 Deficiency, a much more serious issue, in which your bodyoften because of diet or anemiasimply cant get the B12 it needs to continue functioning in a healthy way
Amylyx Pharmaceuticals Post Today, we announced the design of our Phase 3 LUCIDITY clinical trial for our investigational, first-in-class GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia